Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Trimmed by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board reduced its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 49.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 174,021 shares of the biopharmaceutical company's stock after selling 170,837 shares during the period. Canada Pension Plan Investment Board owned approximately 0.13% of Alnylam Pharmaceuticals worth $40,949,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of ALNY. MML Investors Services LLC boosted its position in Alnylam Pharmaceuticals by 5.7% in the 3rd quarter. MML Investors Services LLC now owns 3,086 shares of the biopharmaceutical company's stock valued at $849,000 after buying an additional 166 shares during the last quarter. Sanctuary Advisors LLC boosted its holdings in Alnylam Pharmaceuticals by 91.8% in the third quarter. Sanctuary Advisors LLC now owns 4,558 shares of the biopharmaceutical company's stock valued at $1,254,000 after purchasing an additional 2,181 shares during the last quarter. Tidal Investments LLC grew its stake in Alnylam Pharmaceuticals by 75.1% during the 3rd quarter. Tidal Investments LLC now owns 20,544 shares of the biopharmaceutical company's stock valued at $5,650,000 after purchasing an additional 8,811 shares in the last quarter. American Trust purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $309,000. Finally, Versant Capital Management Inc raised its position in shares of Alnylam Pharmaceuticals by 77.6% in the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 83 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ALNY. Needham & Company LLC reiterated a "buy" rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 9th. Stifel Nicolaus lifted their price target on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. Citigroup upped their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research note on Friday, March 21st. Bank of America increased their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a report on Friday, March 21st. Finally, Sanford C. Bernstein lowered their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $315.58.

Insider Activity

In other news, CMO Pushkal Garg sold 1,548 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total transaction of $389,585.16. Following the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,017,271.63. The trade was a 11.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the sale, the executive vice president now owns 14,321 shares of the company's stock, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 59,984 shares of company stock worth $16,864,347. Insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Price Performance

ALNY stock traded down $0.60 during trading hours on Thursday, hitting $241.38. 200,880 shares of the stock traded hands, compared to its average volume of 872,529. The stock has a 50-day simple moving average of $247.62 and a 200 day simple moving average of $256.40. The company has a market cap of $31.40 billion, a P/E ratio of -111.23 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.